Sarah Holstein, MD, PhD

Sarah Holstein, MD, PhD, associate professor at the University of Nebraska Medical Center, explains her rationale for choosing a triplet regimen over a quadruplet in patients with multiple myeloma.

Holstein does not use quadruplet regimens outside of clinical trials because the treatment paradigm is not quite there, she says. However, she tries to use triplet combinations in the majority of her patients.

Videos

Sarah Holstein, MD, PhD, explains her rationale for choosing a triplet regimen over a quadruplet in patients with multiple myeloma.&nbsp;

Quadruplet Versus Triplet Regimens in Multiple Myeloma

In the updated analysis, the current median follow up for overall survival (OS) was 65 months. When it was previously published, the OS was 34 months. The longer follow up has shown a significant improvement in time to progression for lenalidomide vs placebo.

The patients on the lenalidomide arm have not yet reached a median OS; these patients continue to do very well.

Sarah Holstein, MD, PhD, assistant professor of oncology, Roswell Park Cancer Institute, discusses a randomized study that compared lenalidomide with placebo for patients with multiple myeloma, following a single autologous stem cell transplant (ASCT).

Sarah Holstein, MD, PhD | Authors

Articles

Quadruplet Versus Triplet Regimens in Multiple Myeloma

Lenalidomide vs. Placebo for Multiple Myeloma Patients Following a Single ASCT